drugset / Trial / NCT05125809
Setrusumab vs Placebo for Osteogenesis Imperfecta
RandomizedSequentialQuadruple-blindTreatment
Summary
The primary objectives of the study are to identify a setrusumab dosing strategy in participants with OI and to evaluate the effect of setrusumab vs placebo on reduction in fracture rate.
Timeline
- Start
- 2022-02-21
- Primary completion
- 2025-10-20
- Completion
- 2027-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Setrusumab | Monoclonal antibody | — | Intravenous |